Resistance-associated loss-of-function mutations in genes encoding JAK1 or JAK2 concurrent with deletion of the wild-type allele in patients with metastatic melanoma who had an initial objective tumor regression in response to anti–PD-1. This evidence concerns the gene PDCD1 and metastatic melanoma.